Complete Response in Metastatic Clear Cell Renal Cell Carcinoma Patients Treated with Immune-Checkpoint Inhibitors: Remission or Healing? How to Improve Patients’ Outcomes?

SIMPLE SUMMARY: Immunotherapy-based combinations represent the front-line standard of care for metastatic clear cell renal cell carcinoma (mccRCC) patients. These combinations lead to an overall survival improvement and a dramatic increase of complete response rate raising the question of possible c...

Descripción completa

Detalles Bibliográficos
Autores principales: Thouvenin, Jonathan, Masson, Claire, Boudier, Philippe, Maillet, Denis, Kuchler-Bopp, Sabine, Barthélémy, Philippe, Massfelder, Thierry
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9913235/
https://www.ncbi.nlm.nih.gov/pubmed/36765750
http://dx.doi.org/10.3390/cancers15030793

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9913235/
https://www.ncbi.nlm.nih.gov/pubmed/36765750
http://dx.doi.org/10.3390/cancers15030793

Ejemplares similares